Upadacitinib is efficacious in reducing the alexithymic trait in adult patients with moderate-to-severe atopic dermatitis: a prospective multicenter real-life study.
Eustachio Nettis, Mattia Cristallo, Carmen S Fiorella, Angela Giuliani, Vincenzo Patella, Luciana Pierro, Tiziana Peduto, Giuseppe F Amoruso, Genoveffa Scotto DI Luzio, Pietro Morrone, Martino Carriero, Pierfrancesco DE Giacomo, Massimo Triggiani, Isabella Carrieri, Ippolita Zaza, Francesco Pugliese, Marina Castriota, Stefano Pellè
{"title":"Upadacitinib is efficacious in reducing the alexithymic trait in adult patients with moderate-to-severe atopic dermatitis: a prospective multicenter real-life study.","authors":"Eustachio Nettis, Mattia Cristallo, Carmen S Fiorella, Angela Giuliani, Vincenzo Patella, Luciana Pierro, Tiziana Peduto, Giuseppe F Amoruso, Genoveffa Scotto DI Luzio, Pietro Morrone, Martino Carriero, Pierfrancesco DE Giacomo, Massimo Triggiani, Isabella Carrieri, Ippolita Zaza, Francesco Pugliese, Marina Castriota, Stefano Pellè","doi":"10.23736/S2784-8671.25.08228-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Upadacitinib has proven to be well tolerated and provided superior efficacy compared to dupilumab after 16 weeks of treatment in adult patients with moderate-to-severe atopic dermatitis (AD) in randomized clinical trials.</p><p><strong>Methods: </strong>This multicentric, prospective, observational, real-life study included 120 adult patients with moderate-to-severe AD treated with Upadacitinib at 10 Italian hospitals. We examined both physician-reported outcome measures (EASI), patient-reported outcome measures (itch, sleep and pain score [NRS], Dermatology Life Quality Index [DLQI], alexithymia [TAS-20 score]), and serological markers after 16 weeks.</p><p><strong>Results: </strong>A statistically significant reduction was recorded in all the scores analyzed, including the TAS-20 score (P<0.0001). The median (IQR) change from baseline to 16 weeks of treatment in the EASI score was 90.1 (11.3) (P<0.0001). The EASI50, EASI75 and EASI90 response rates were 95.8%, 82.5%, 50.8% (P<0.0001).</p><p><strong>Conclusions: </strong>This is the broadest multicenter real-life study in AD patients treated with upadacitinib, analyzing the reduction of the TAS-20 score. Noteworthy is the rapidity of drug effectiveness in reducing the extension of lesions and itching after just four weeks.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":"160 5","pages":"398-405"},"PeriodicalIF":2.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Italian Journal of Dermatology and Venereology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S2784-8671.25.08228-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Upadacitinib has proven to be well tolerated and provided superior efficacy compared to dupilumab after 16 weeks of treatment in adult patients with moderate-to-severe atopic dermatitis (AD) in randomized clinical trials.
Methods: This multicentric, prospective, observational, real-life study included 120 adult patients with moderate-to-severe AD treated with Upadacitinib at 10 Italian hospitals. We examined both physician-reported outcome measures (EASI), patient-reported outcome measures (itch, sleep and pain score [NRS], Dermatology Life Quality Index [DLQI], alexithymia [TAS-20 score]), and serological markers after 16 weeks.
Results: A statistically significant reduction was recorded in all the scores analyzed, including the TAS-20 score (P<0.0001). The median (IQR) change from baseline to 16 weeks of treatment in the EASI score was 90.1 (11.3) (P<0.0001). The EASI50, EASI75 and EASI90 response rates were 95.8%, 82.5%, 50.8% (P<0.0001).
Conclusions: This is the broadest multicenter real-life study in AD patients treated with upadacitinib, analyzing the reduction of the TAS-20 score. Noteworthy is the rapidity of drug effectiveness in reducing the extension of lesions and itching after just four weeks.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
